Trial Profile
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Mar 2024
Price :
$35
*
At a glance
- Drugs Belzupacap sarotalocan (Primary)
- Indications Uveal melanoma
- Focus Registrational; Therapeutic Use
- Acronyms CoMpass
- Sponsors Aura Biosciences
- 27 Mar 2024 According to an Aura Biosciences media release, R&D expenses increased to $20.3 million and $65.2 million for the three months and full year ended Dec 31, 2023, respectively, from $13.2 million and $42.2 million for the three months and full year ended Dec 31, 2022, respectively, primarily due to ongoing clinical costs associated with the progression of the Phase 2 study and CRO costs associated with the start of the Phase 3 global trial, and manufacturing and development costs for bel-sar.
- 27 Mar 2024 According to an Aura Biosciences media release, the trial is actively enrolling in the U.S. with a strong endorsement from the ocular oncology community. The Company is on track to activate sites and enroll patients globally throughout 2024.
- 07 Dec 2023 According to an Aura Biosciences media release, first patient has been dosed in this trial.